Prexasertib Completed Phase 2 Trials for Triple-Negative Breast Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04032080LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer